Delveinsight launched a new report on Benign Prostatic Hyperplasia Pipeline Insights 2020.
DelveInsight’s “Benign Prostatic Hyperplasia Pipeline Insights, 2021,” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Benign Prostatic Hyperplasia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Benign prostatic hyperplasia: Overview
Benign prostatic hyperplasia (BPH) refers to the change in the size of the prostate and not the potential symptoms that it may cause, which are usually referred to as lower urinary tract symptoms (LUTS). LUTS may be primarily irritative, obstructive, or mixed. Men with BPH may be asymptomatic, respond to lifestyle changes, or require medical or surgical therapy; symptoms are more common as men age.
Click here and read more about Benign Prostatic Hyperplasia Pipeline Insights 2020.
Symptoms
The symptoms of Benign prostatic hyperplasia include:
- Obstructive Symptoms – Sensation of incomplete bladder emptying, Straining to void, Urinary hesitancy, Weak urinary stream
- Irritative Symptoms – Dysuria, Nocturia, Urinary frequency, Urinary urgency
Diagnosis
Several key diagnostic tools and investigations are used to diagnose BPH in men who present with LUTS. The first and most important tool in the assessment and diagnosis of BPH is the medical history of the patient. By taking a detailed history, one can establish potential causes and relevant comorbidities of LUTS, some of which might contribute to LUTS. A physical examination, including a digital rectal examination (DRE) and urinalysis, is the next step in the diagnosis. Further investigations, such as uroflowmetry and measuring PVR volume, should help to confirm the presence of obstructive symptoms attributable to BPH.
Treatment
Pharmacologic treatment- Men with moderate to severe LUTS from BPH (AUASI score of 8 or higher) or mild LUTS that are deemed bothersome by the patient may be offered pharmacologic treatment. The 2 major classes of medications for BPH are alpha-adrenergic blockers and 5-alpha reductase inhibitors. The PDE-5 inhibitor tadalafil is also approved by the Food and Drug Administration (FDA) for the treatment of BPH.
Non Pharmacologic treatment- In men with mild LUTS symptoms from BPH (usually defined as an AUASI score of 0–7), medical or surgical treatment is not required. In the Medical Therapy of Prostatic Symptoms Study,23 fewer than 5% of men with mild symptoms who did not receive treatment had a progression of their symptoms as defined by a 4-point or greater increase in their AUASI score. No cases of acute kidney injury due to obstructive uropathy occurred.
Benign prostatic hyperplasia Emerging Drugs
- Topsalysin: Sophiris Bio
- OPK88004: Eli Lilly and Company
Request for sample pages: https://www.delveinsight.com/sample-request/benign-prostatic-hyperplasia-bph-pipeline-insight
Phases
DelveInsight’s report covers around 30+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Benign prostatic hyperplasia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Parenteral
- intravitreal
- Subretinal
- Topical.
- Molecule Type
Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Drugs have been categorized under various product types like Mono, Combination, and Mono/Combination.
Table of contents:
- Introduction
- Executive Summary
- Benign prostatic hyperplasia: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Benign prostatic hyperplasia – DelveInsight’s Analytical Perspective
- In-depth Commercial Assessment
- Benign prostatic hyperplasia Collaboration Deals
- Late Stage Products (Phase III)
- Topsalysin: Sophiris Bio
- Mid Stage Products (Phase II)
- OPK88004: Eli lilly and Company
- Early Stage Products (Phase I)
- Fadanafil: XuanZhu Pharma
- Pre-clinical and Discovery Stage Products
- Lenvatinib: Aiviva BioPharma
- Inactive Products
- Benign prostatic hyperplasia Key Companies
- Benign prostatic hyperplasia Key Products
- Benign prostatic hyperplasia – Unmet Needs
- Benign prostatic hyperplasia – Market Drivers and Barriers
- Benign prostatic hyperplasia – Future Perspectives and Conclusion
- Benign prostatic hyperplasia Analyst Views
- Benign prostatic hyperplasia Key Companies
- Appendix
View report: https://www.delveinsight.com/report-store/benign-prostatic-hyperplasia-bph-pipeline-insight
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/